Biodistribution Studies

Preclinical and clinical phase studies generally check different parameters of drugs. The use of vectors for gene therapy requires an evaluation of the vector biodistribution during preclinical phases and the vector biodissemination during the clinical phases I/II.

Texcell has developed study plans to detect virus/vectors or specific gene sequences in a variety of different samples and fluids (see table below).

After DNA extraction, specific virus/vector and/or transgene DNA sequences are detected by using quantitative PCR.

Adrenals Mammary gland area Sciatic nerve
Aorta Mesenteric artery Semen
Brain stem : pool medulla + pons Nasal secretion Seminal vesicles (male)
Cerebellum eye : retina+ superior eyelid Skeletal muscle (Muscle squelettique)
Cerebrum : cerebral cortex Oesophagus Skin
Epididymides (male) Optic nerve Spleen
Faeces Ovaries (female) Sternum with bone marrow
Femoral Bone with articulation : femur + femoral articulation Oviducts (female) Stomach (fundus)
Gall bladder Pancreas Testes (male)
Heart PBMCs Throat swabs
Injection sites Peyer’s patches Thymus
Kidneys Pituitary gland Thyroids + parathyroids
Knee joint Plasma Tongue
Larynx Pool caecum + colon + rectum Trachea
Liver Pool ileum + jejunum + duodenum Ureters
Lungs with bronchi Pool pia matters (cervical + lumbar + thoracic) Urinary bladder
Lymph nodes (cervical) Pool spinal cord regions (cervical + lumbar + thoracic) Urine
Lymph nodes (iliac) Pool thalamus + hypothalamus Uterus corpus + cervix (female)
Lymph nodes (mandibular) Prostate (male) Vagina (female)
Lymph nodes (mesenteric) Saliva Vaginal secretion
Lymph nodes (popliteal) Salivary glands (parotid et submandibular)

Texcell can propose a state-of-the-art protocol that meets your specific requirements.